CD8A and nonpapillary renal cell carcinoma: To explore the clinical implication of CD8+ T cells in ccRCC, we divided ccRCC patients of TCGA into two groups (High CD8+ T lymphocytes: Top 45% and Low CD8+ T lymphocytes: Bottom 45%).